Oral Antidiabetic Drugs in Research and Development

  • H. Bischoff
  • H. E. Lebovitz
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 119)


Current oral antidiabetic therapy has numerous pharmacologically efficacious drugs at its disposal — the recognized sulfonylurea and biguanide derivatives — and, more recently, the α-glucosidase inhibitors. However, a review of the experience with the well-established sulfonylurea and biguanide drugs bears out that the ultimate goal of antidiabetic drug therapy, the prevention of diabetic complications, cannot as yet be met satisfactorily.


Insulin Secretion Fatty Acid Oxidation Insulin Release Hepatic Glucose Production Oral Antidiabetic Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agius L, Alberti KGMM (1985) Regulation of flux through pyruvate dehydrogenase and pyruvate carboxylase in rat hepatocytes. Effect of fatty acids and glucagon. Eur J Biochem 152:699–707PubMedGoogle Scholar
  2. Agius L, Pillay D, Alberti KGMM, Sherratt HSA (1985) Effects of 2[5(4-chloro-phenylpentyl] oxirane-2-carboxylate on fatty acid synthesis and fatty acid oxidation in isolated rat hepatocytes. Biochem Pharmacol 34:2651–2654PubMedGoogle Scholar
  3. Angel I, Schoemaker H, Duval N, Oblin A, Sevrin M, Langer SZ (1990) SL 84.0418: a new α 2-antagonist with anti-hyperglycemic properties. Eur J Pharmacol 183:990–991aGoogle Scholar
  4. Angel I, Schoemaker H, Arbilla S, Galzin AM, Berry CN, Niddam R, Pimoule C, Sevrin M, Wick A, Langer SZ (1992) SL 84.0418: a novel, potent and selective alpha-2 adrenoceptor antagonist: I. In vitro pharmacological profile. J Pharmacol Exp Ther 263:1327PubMedGoogle Scholar
  5. Angel I, Grosset A, Perault G, Schoemaker H, Langer SZ (1993) In vivo pharmacological profile of SL 84.0418, a new selective, peripherally active α 2-adrenoceptor antagonist. Eur J Pharmacol 234:137–145PubMedGoogle Scholar
  6. Asins G, Serra D, Hegardt FG (1994) The effect of etomoxir on the mRNA levels of enzymes involved in ketogenesis and cholesterogenesis in rat liver. Biochem Pharmacol 47:1373–1379PubMedGoogle Scholar
  7. Bailey CJ, Flatt PR (1989) Alkylglycidates. Diabetes 39:231–236Google Scholar
  8. Bechern M, Hebisch S, Schramm M (1988) Ca2+ agonists: new, sensitive probes for Ca2+ channels. Trends Pharmacol Sci 9:257–261Google Scholar
  9. Beck-Nielsen H, Hother-Nielsen O, Vaag A, Alford F (1994) Pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: the role of skeletal muscle glucose uptake and hepatic glucose production in the development of hyperglycaemia. A critical comment. Diabetologia 37:217–221PubMedGoogle Scholar
  10. Beneking M, Oellerich M, Haeckel R, Binder L (1987) Inhibition of mitochondrial carnitine acylcarnitine translocase-mediated uptake of carnitine by 2-(3-methyl-cinnamyl-hydrazono)-propionate. J Clin Chem Clin Biochem 25:467–471PubMedGoogle Scholar
  11. Berlin I, Rosenzweig P, Fusean E, Molinier P, Morselli P (1991) Effect of a new alpha-2 adrenoceptor blocking compound (SL 84.0418) on C-peptide and insulin responses to glucose infusion in healthy subjects. Diabetologia 34.A107Google Scholar
  12. Berlin I, Rosenzweig P, Fusean E, Chalon S, Puech AJ (1992) The new alpha-2 adrenoceptor blocking compound (SL 84.0418) inhibits blood glucose increase following oral glucose tolerance test in healthy subjects. Diabetologia 35:A201Google Scholar
  13. Berridge TL, Doxey JC, Roach AG, Smith CF (1992) Selectivity profile of the alpha-2 adrenoceptor antagonist efaroxan in relation to plasma glucose and insulin levels in the rat. Eur Pharmacol 213:205–212Google Scholar
  14. Bliesath H, Haupt E, Lühmann R, Hoppe FU, Radtke HW (1987) First administration of etomoxir to type 2 (non-insulin-dependent) diabetic patients. Diabetologia 30:501AGoogle Scholar
  15. Blondel O, Bailbe D, Portha B (1989) In vivo insulin resistance in streptozotocin-diabetic rats. Evidence for reversal following oral vanadate treatment. Diabetologia 32:185–190PubMedGoogle Scholar
  16. Boulton AJM, Levin S, Comstock J (1990) A multicentre trial of the aldose-reductase inhibitor tolrestat in patients with symptomatic diabetic neuropathy. Diabetologia 33:431–437PubMedGoogle Scholar
  17. Brichard SM, Bailey CJ, Henquin JC (1990) Marked improvement of glucose homeostasis in diabetic ob/ob mice given oral vanadate. Diabetes 39:1326–1332PubMedGoogle Scholar
  18. Brown CA, Chan SLF, Stillings MR, Smith SA, Morgan NG (1993) Antagonism of the stimulatory effects of efaroxan and glibenclamide in rat pancreatic islets by the imidazoline, RX 801080. Br J Pharmacol 110:1017–1022PubMedGoogle Scholar
  19. Brownlee M (1994) Glycation and diabetic complications. Diabetes 43:836–841PubMedGoogle Scholar
  20. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A (1986) Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232: 1629–1632PubMedGoogle Scholar
  21. Bucala R, Makita Z, Vega G, Grundy S et al. (1994) Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and end stage renal insufficiency. Proc Natl Acad Sci USA 91: 9441–9445PubMedGoogle Scholar
  22. Cam MC, Pederson RA, Brownsey RW, McNeill JH (1993) Longterm effectiveness of oral vanadyl sulphate in streptozotocin-diabetic rats. Diabetologia 36: 218–224PubMedGoogle Scholar
  23. Cameron NE, Cotter MA, Dines K, Love A (1992) Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 35:946–950PubMedGoogle Scholar
  24. Chan SLF, Morgan NG (1990) Stimulation of insulin secretion by efaroxan may involve interaction with potassium channels. Eur J Pharmacol 176:97–101PubMedGoogle Scholar
  25. Chang AY, Wyse BM, Gilchrist BJ, Peterson T, Diani AR (1983a) Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters and normal and streptozotocin-diabetic rats. Diabetes 32:830–838PubMedGoogle Scholar
  26. Chang AY, Wyse BM, Gilchrist BJ (1983b) Ciglitazone, a new hypoglycemic agent. II. Effect on glucose and lipid metabolisms and insulin binding in the adipose tissue of C57BL/6J ob/ob and — + ? mice. Diabetes 32:839–845PubMedGoogle Scholar
  27. Chen YDI, Golay A, Swislock ALM, Reaven GM (1987) Resistance to insulin suppression of plasma free fatty acid concentrations and insulin stimulation of glucose uptake in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64:17–21PubMedGoogle Scholar
  28. Ciaraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich RA (1990) In vitro studies on the action of CS 045, a new antidiabetic agent. Metabolism 39: 1056–1062PubMedGoogle Scholar
  29. Colca JR, Wyse BM, Sawada G, Jodelis KS, Connell CL et al. (1988) Ciglitazone, a hypoglycemic agent: early effects on pancreatic islets of ob/ob mice. Metabolism 37:276–280PubMedGoogle Scholar
  30. Consoli A (1992) Role of liver in pathophysiology of NIDDM. Diabetes Care 15:430–441PubMedGoogle Scholar
  31. Consoli A, Nurjhan N, Capani F, Gerich J (1989) Predominant role of glucone-ogenesis in increased hepatic glucose production in NIDDM. Diabetes 38: 550–557PubMedGoogle Scholar
  32. Cooper AJ, Keddie KMG (1964) Hypotensive collapse and hypolycemia after mebanazine, a monoamine oxidase inhibitor. Lancet 1:1133–1135PubMedGoogle Scholar
  33. Dai S, Thompson KH, McNeill JH (1994) One-year treatment of streptozotocin-induced diabetic rats with vanadyl sulphate. Pharmacol Toxicol 74:101–109PubMedGoogle Scholar
  34. Deaciuc IV, Kühnle HF, Strauss KM, Schmidt FH (1983) Studies on the mechanism of action of the hypoglycemic agent, 2-(3)methylcinnamylhydrazono)-propionate(BM 42.304). Biochem Pharmacol 32:3405–3412PubMedGoogle Scholar
  35. Dean PM, Matthews EK (1970) Glucose-induced electrical activity in pancreatic islet cells. J Physiol 210:255–64PubMedGoogle Scholar
  36. DeFronzo RA (1988) The triumvirate: B-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37:667–687PubMedGoogle Scholar
  37. DeFronzo RA (1992) Pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: a balanced overview. Diabetologia 35:389–397PubMedGoogle Scholar
  38. DeFronzo RA, Ferrannini E, Simonson D (1989) Fasting hyperglycemia in noninsulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 38:387–395PubMedGoogle Scholar
  39. Dhalla NS, Elimbam V, Rupp H (1992) Paradoxical role of lipid metabolism in heart function and dysfunction. Mol Cell Biochem 116:3–9PubMedGoogle Scholar
  40. Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977–986Google Scholar
  41. Domingo JL, Ortega A, Llobet JM, Keen CL (1991a) No improvement of glucose homeostasis in diabetic rats by vanadate treatment when given by gavage. Trace Elem Med 8:181–186Google Scholar
  42. Domingo JL, Comez M, Llobet JM, Corbella J, Keen CL (1991b) Oral vanadium administration to streptozotocin-diabetic rats has marked negative side effects which are independent of the form of vanadium used. Toxicology 66:279–287PubMedGoogle Scholar
  43. Domingo JL, Gomez M, Sanchez DJ, Llobet JM, Keen CL (1992) Tiron administration minimizes the toxicity of vanadate but not its insulin mimetic properties. Life Sci 50:1311–1317PubMedGoogle Scholar
  44. Donaubauer HH, Mayer D (1993) Acute, subchronic and chronic toxicity of the new sulfonylurea glimepiride in rats. Arzneim-Forsch/Drug Res 43:547–549Google Scholar
  45. Edelstein D, Brownlee M (1992) Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia 35:96–97PubMedGoogle Scholar
  46. Eistetter K, Wolf HPO (1982) Synthesis and hypoglycemic activity of phenylal-kyloxiranecarboxylic acid derivatives. J Med Chem 25:109–113PubMedGoogle Scholar
  47. Eistetter K, Wolf HPO (1986) Etomoxir. Drugs of the Future 11:1034–1036Google Scholar
  48. Florkowski CM, Rowe BR, Nightingale S, Harvey TC, Barnett AH (1991) Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy. Diabetes 40:129–133PubMedGoogle Scholar
  49. Foley JE (1992) Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus. Diabetes Care 15:773–784PubMedGoogle Scholar
  50. Frøkjær-Jensen J, Kofod H, Godtfredsen SE (1992) Mechanism of action of AG-EE 623 ZW, a novel insulintropic agent. Diabetologia 35:Al 16Google Scholar
  51. Fujita T, Sugiyama Y, Taketomi S, Sohda T et al. (1983) Reduction of insulin resistance in obese and/or diabetic animals by Ciglitazone, a new antidiabetic agent. Diabetes 32:804–810PubMedGoogle Scholar
  52. Fujitani S, Yada T (1994) A novel D-phenylalanine-derivative hypoglycemic agent A-4166 increase cytosolic free Ca2+ in rat pancreatic beta-cells by stimulating Ca2+ influx. Endocrinology 134:1395–1400PubMedGoogle Scholar
  53. Fujiwara T, Yoshioka S, Yoshioka T, Usiyama I, Horikoshi H (1988) Characterization of new oral antidiabetic agent CS 045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549–1558PubMedGoogle Scholar
  54. Geisen K (1988) Special pharmacology of the new sulfonylurea glimepiride. Arzneim-Forsch/Drug Res 38:1120–1130Google Scholar
  55. Geisen K, Hübner M, Hitzel V, Hrstka VE, Pfaff W, Bosies E, Regitz G, Kühnle HF, Schmidt FH, Weyer R (1978) Acylaminoalkyl-substituierte Benzoe- und Phenylalkansäuren mit blutglukosesenkender Wirkung. Arzneim-Forsch 28: 1081–1083Google Scholar
  56. Gerich JE (1991) Is muscle the major site of insulin resistance in type 2 (non-insulin-dependent) diabetes mellitus? Diabetologia 34:607–610PubMedGoogle Scholar
  57. Gill AM, Yen TT (1991) Effects of ciglitazone on endogenous plasma islet amyloid polypeptide and insulin sensitivity in obese-diabetic viable yellow mice. Life Sci 48:703–710PubMedGoogle Scholar
  58. Gugliano D, Martella R, Quartraro A, Rosa N et al. (1993) Tolrestat for mild diabetic neuropathy. Ann Intern Med 118:7–11Google Scholar
  59. Goldberg LI (1964) Monoamine oxidase inhibitors, adverse reactions and possible mechanisms. JAMA 190:456–462PubMedGoogle Scholar
  60. Grell W, Greischel A, Zahn G, Mark M, Knorr H, Rupprecht E, Müller U (1993) (S)(+)-2-ethoxy-4-[N-[l-(2-piperidinophenyl)-3-methyl-1-butyl[aminocar-bonylmethyl]-benzoic acid. PCT: WO 93/00337 (07.01.93)Google Scholar
  61. Groop LC, Bonadonna RC, DelPrato S, Ratheiser K, Zyck K, Ferrannini E, DeFronzo RA (1989) Glucose and free fatty acid metabolism in noninsulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 84:205–213PubMedGoogle Scholar
  62. Groop LC, Bonadonna RC, Shank M, Petrides AS, DeFronzo RA (1991) Role of free fatty acids and insulin in determining free fatty acid and lipid oxidation in man. J Clin Invest 87:83–89PubMedGoogle Scholar
  63. Haeckel R, Oellerich M (1979) Hydrazonopropionic acids, a new class of hypoglycemic substances. 1. Hypoglycemic effect of 2-(phenylethylhydrazono).- and 2-(2-cyclohexylethylhydrazono)-propionic acid. Horm Metab Res 11:606–611PubMedGoogle Scholar
  64. Haeckel R, Terlutter H, Schumann G, Oellerich M (1984) Hydrazonopropionic acids, a new class of hypoglycaemic substances. 3. Inhibition of jejunal glucose uptake in the rat and guinea pig. Horm Metab Res 16:423–427PubMedGoogle Scholar
  65. Haeckel R, Oellerich M, Schumann G, Beneking M (1985) Hydrazonopropionic acids, a new class of hypoglycemic substances. 5. Inhibition of hepatic glucone-ogenesis by 2-(3-methylcinnamyl-hydrazono)-propionate in the rat and guinea pig. Horm Metab Res 17:115–122PubMedGoogle Scholar
  66. Hammes H-P, Martin S, Federlin K, Gersen K, Brownlee M (1991) Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 88:11555–11558PubMedGoogle Scholar
  67. Hanson RL, Isaacson CM (1985) Stimulation of insulin secretion from isolated rat islets by SaRI 59–801. Relation to cAMP concentration and Ca2+-uptake. Diabetes 34:691–695PubMedGoogle Scholar
  68. Hanson RL, Isaacson CM, Boyajy LD (1985) Stimulation of insulin secretion from isolated rat islets by SaRI 59–801. Diabetes 34:548–552PubMedGoogle Scholar
  69. Häring HU, Mehnert H (1993) Pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: candidates for a signal transmitter defect causing insulin resistance of the skeletal muscle. Diabetologia 36:176–182PubMedGoogle Scholar
  70. Haupt E, Bliesath H, Hoppe FU, Lühmann R, Wolf HPO, Radtke HW (1988) Treatment of type 2 diabetic patients (NIDDM) with different dosages of etomoxir: a placebo controlled drf-study. Diabetes Res Clin Pract 5:S615Google Scholar
  71. Henquin JC, Meissner HP (1981) Effects of amino acids on membrane potential and 86Rb fluxes in pancreatic B-cells. Am J Physiol 240:E245–E252PubMedGoogle Scholar
  72. Henquin JC, Meissner HP (1984) Significance of ionic fluxes and changes in membrane potential for stimulus-secretion coupling in pancreatic B-cell. Experientia 40:1043–1052PubMedGoogle Scholar
  73. Henquin JC, Schmeer W, Nenquin M, Meissner HP (1985) Effects of a calcium channel agonist on the electrical, ionic and secretory events in mouse pancreatic B-cells. Biochem Biophys Res Commun 131:980–986PubMedGoogle Scholar
  74. Henquin JC, Garrino MG, Nenquin M (1987) Stimulation of insulin release by benzoic acid derivatives related to the non-sulphonylurea moiety of glibenclamide: structural requirements and cellular mechanisms. Eur J Pharmacol 141:243–251PubMedGoogle Scholar
  75. Heyliger CE, Tahiliani AG, McNeill JH (1985) Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science 227:1474–1477PubMedGoogle Scholar
  76. Hirose H, Maruyama H, Ito K, Seto Y, Koyama K, Dan K, Saruta T, Kato R (1994) Effects of N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166) on insulin and glucagon secretion in isolated perfused rat pancreas. Pharmacology 48:205–210PubMedGoogle Scholar
  77. Ho RS, Wiseberg JJ, Brand LJ, Nadelson J, Boyajy (1985) A novel, orally effective hypoglycemic agent, SaRI 59–801, in laboratory animals. Drug Dev Res 6:67–77Google Scholar
  78. Ho W, Tutwiler GF, Cottrell SC, Morgans DJ, Tarhan D, Mohrbacher RJ (1986) Alkylglycidic acids: potential new hypoglycemic agents. J Med Chem 29:2184–2190PubMedGoogle Scholar
  79. Hofmann CA, Colca JR (1992) New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care 35:1075–1078Google Scholar
  80. Hofmann CA, Lorenz K, Colca JR (1991) Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinology 129:1915–1925PubMedGoogle Scholar
  81. Hofmann CA, Edwards CW 3rd, Hillmann RM, Colca JR (1992) Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: evaluation of liver GLUT 2 and phosphoenolpyruvate carboxykinase expression. Endocrinology 130:735–740PubMedGoogle Scholar
  82. Hubinger A, Knode O, Susanto F, Reinauer H, Gries FA (1993) Effects of etomoxir on insulin sensitivity, energy expenditure and substrate oxidation in NIDDM. Diabetologia 36:A75Google Scholar
  83. Ikeda H, Taketomi S, Sugiyama Y, Shimura Y, Sodha T, Meguro K, Fujita T (1990) Effects of pioglitazone on glucose and lipid metabolism in normal and insulin-resistant animals. Arzneimittel-Forschung 40:156–162PubMedGoogle Scholar
  84. Iwamoto Y, Kuzuya T, Matsuda A, Awata T, Kumakura S et al. (1991) Effect of new oral antidiabetic agent CS 045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 14:1083–1086PubMedGoogle Scholar
  85. Iwanishi M, Kobayashi M (1993) Effect of pioglitazone on insulin receptors of skeletal muscles from high fat fed rats. Metabolism 42:1017–1021PubMedGoogle Scholar
  86. Jennings PE, Nightingale S, Le Guew C, Lawson N et al. (1990) Prolonged aldose reductase inhibition in chronic peripheral diabetic neuropathy: effects on microangiopathy. Diabetic Medicine 7:63–68PubMedGoogle Scholar
  87. Johnson DG, Dickerson J, Rutala P, Bressler R (1980) Clinical evaluation of pirogliride in patients with maturity-onset diabetes. Clin Res 28:81AGoogle Scholar
  88. Johnson DG, Goebel CV, Hruby VJ, Bregman MD, Trivedi D (1981) Decrease in hyperglycemia of diabetic rats by a glucagon receptor antagonist. Science 215:1115–1116Google Scholar
  89. Jonas JC, Plant TD, Henquin JC (1992) Imidazoline antagonists of α 2-adrenoceptors increase insulin release in vitro by inhibiting ATP-sensitive K+ channels in pancreatic B-cells. Br J Pharmacol 107:8–14PubMedGoogle Scholar
  90. Kador PF, Robison WG Jr, Kinoshita JH (1985) The pharmacology of aldose reductase inhibitors. Annu Rev Pharmacol Toxicol 25:691–714PubMedGoogle Scholar
  91. Kahn CR (1995) The insulin receptor, insulin action and the mechanims of insulin resistance in diabetes and atherosclerosis. In: Schwartz CJ, Born GVR (eds) New horizons in diabetes mellitus and cardiovascular disease. Current Science, London, pp 46–56Google Scholar
  92. Kameda K, Ono S, Abiko Y (1982a) Hypoglycemic action of 2-[2(4,5-dihydro-lH-imidazol-2-yl)-1-phenylethyl]pyridine dihydrochloride sesquihydrate (DG-5128), a new hypoglycemic agent. Arzneim-Forsch/Drug Res 32:39–44Google Scholar
  93. Kameda K, Ono S, Koyama I, Abiko Y (1982b) Insulin releasing action of 2-[2(4,5-dihydro-lH-imidazol-2-yl)-1-phenylethyl]pyridine dihydrochloride sesquihydrate (DG-5128), a new, orally effective hypoglycaemic agent. Acta Endocrinol 99:410–415PubMedGoogle Scholar
  94. Kanamaru T, Shinagawa S, Asai M, Okazaki H, Sugiyama Y, Fujita T, Iwatsuka H, Yoneda M (1985) Emeriamine, an antidiabetic β-aminobetaine derived from a novel fungal metabolite. Life Sci 37:217–223PubMedGoogle Scholar
  95. Kawazu S, Suzuki M, Negishi K, Ishii J, Sando H, Katagiri H, Kanazawa Y, Yamanouchi S, Akanuma Y, Kajinuma H, Suzuki K, Watanabe K, Itoh T, Kobayashi T, Kosaka K (1987) Initial phase II clinical studies on midaglizole (DG-5128). A new hypoglycemic agent. Diabetes 36:221–226PubMedGoogle Scholar
  96. Kern TS, Engerman RL (1991) Development of complication in diabetic dogs and galactosemic dogs: effect of aldose reductase inhibitors. In: Proceedings of a workshop on aldose reductase inhibitors. NIH, Bethesda, publication 81–3114Google Scholar
  97. Kirchain WR, Rendell MS (1990) Aldose reductase inhibitors. Pharmacotherapy 10:326–336PubMedGoogle Scholar
  98. Kletzien RF, Clarke SD, Ulrich PG (1992) Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol 41:393–398PubMedGoogle Scholar
  99. Kobayashi M, Iwanishi M, Egawa K, Shigeta Y (1992) Pioglitazone increases insulin sensitivity by activating insulin receptor kinase. Diabetes 41:476–483PubMedGoogle Scholar
  100. Kolterman O, Gary R, Griffin J, Burstein P, Insel J, Scarlett J, Olefsky J (1981) Receptor and postreceptor defects contribute to the insulin resistance in non-insulin-dependent diabetes mellitus. J Clin Invest 68:957–969PubMedGoogle Scholar
  101. Komatsu M, Rokokawa N, Takeda T, Nagasawa Y, Aizawa T, Yamada T (1989) Pharmacological characterization of the voltage-dependent calcium channel of pancreatic B-cell. Endocrinology 125:2008–2014PubMedGoogle Scholar
  102. Koundakjian PP, Turnbull DM, Bone AJ, Rogers MP, Younan SIM, Sherratt HSA (1984) Metabolic changes in fed rats caused by chronic administration of ethyl 2-[5-(4-chlorophenyl)pentyl] oxirane-2-carboxylate, a new hypoglycaemic compound. Biochem Pharmacol 33:465–473PubMedGoogle Scholar
  103. Kraegen EW, James DE, Jenkins AB, Chisholm DJ, Storlien LH (1989) A potent in vivo effect of ciglitazone on muscle insulin resistance induced by high fat feeding of rats. Metabolism 38:1089–1093PubMedGoogle Scholar
  104. Krentz AJ, Honigsberger L, Ellis SH, Hardman M, Nattrass M (1992) A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy. Diabet Med 9:463–468PubMedGoogle Scholar
  105. Kreutter DK, Andrews KM, Gibbs EM, Hutson NJ, Stevenson RW (1990) Insulinlike activity of new antidiabetic agent CP 68722 in 3T3-L1 adipocytes. Diabetes 39:1414–1419PubMedGoogle Scholar
  106. Kühnle HF, Schmidt FH, Deaciuc IV (1984) In vivo and in vitro effects of a new hypoglycemic agent, 2-(3-methylcinnamylhydrazono)-propionate (BM 42.304) on glucose metabolism in guinea pigs. Biochem Pharmacol 33:1437–1444PubMedGoogle Scholar
  107. Kuzuya T, Iwamoto Y, Kosaka K, Takebe K, Yamanouchi T et al. (1991) A pilot clinical trial of a new oral hypoglycemic agent CS 045 in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 11:147–153PubMedGoogle Scholar
  108. Lebovitz HE (1995) The metabolic disease syndrome: lessons to be learned from radical and ethnic diversity. In: Schwartz CJ, Born GVR (eds) Diabetes mellitus and cardiovascular disease. Current Science, London, pp 75–80Google Scholar
  109. Lebovitz HE, Chaiken RL (1994) Insulin-sensitizing and insulin-mimetic agents as potential treatment modalities for non-insulin-dependent diabetes mellitus. Av Diabetol 9:27–32Google Scholar
  110. Lilly K, Chung C, Kerner J, Van Renterghem R, Bieber LL (1992) Effect of etomoxiryl-CoA on different carnitine acyltransferases. Biochem Pharmacol 43:353–361PubMedGoogle Scholar
  111. Macleod AF, Boulton AJ, Owens DR, van Rooy P et al. (1992) A multicentre trial of the aldose-reductase inhibitor tolrestat in patients with symptomatic diabetic peripheral neuropathy. North European Tolrestat Study Group. Diabete Metab 18:14–20PubMedGoogle Scholar
  112. Malabu UH, Dryden S, McCarthy HD, Kilpatrick A, Williams G (1994) Effect of chronic vanadate admimistration in the STZ-induced diabetic rat: the antihyper-glycemic action of vanadate is attributable entirely to its suppression of feeding. Diabetes 43:9–15PubMedGoogle Scholar
  113. Malaisse WJ (1990) Regulation of insulin release by the intracellular mediators cyclic AMP, Ca2+, inositol 1,4,5-trisphosphate, and diacylglycerol. In: Cuatrecasas P, Jacobs S (eds) Insulin. Springer, Berlin Heidelberg New York, pp 113–124 (Handbook of experimental pharmacology, vol 92)Google Scholar
  114. Malaisse WJ, Sener A (1981) Calcium antagonists and islet function. XII. Comparison between nifedipine and chemically related drugs. Biochem Pharmacol 30: 1039–1041PubMedGoogle Scholar
  115. Malaisse-Lagae F, Mathias PCF, Malaisse WJ (1984) Gating and blocking of calcium channels by dihydropyridines in the pancreatic B-cell. Biochem Biophys Res Commun 123:1062–1068PubMedGoogle Scholar
  116. Malaisse WJ, Lebrun P, Sener A (1993) Modulation of the insulinotropic action of glibenclamide and glimepiride by nutrient secretagogues in pancreatic islets from normoglycemic and hyperglycemic rats. Biochem Pharmacol 45:1845–1849PubMedGoogle Scholar
  117. McGarry JD, Foster DW (1980) Regulation of hepatic fatty acid oxidation and ketone body production. Annu Rev Biochem 49:395–420PubMedGoogle Scholar
  118. Morgan NG, Chan SLF, Dumme MJ (1991) Stimulation of insulin secretion by α 2-antagonists is due to blockade of ATP-sensitive potassium channels. Diabetes 40 [Suppl l]:79aGoogle Scholar
  119. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J (1994) Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188–1193PubMedGoogle Scholar
  120. Oellerich M, Haeckel R (1980) Hydrazonopropionic acids, a new class of hypoglycemic substances. 2. Influence of 2-(phenylethyl-hydrazono)- and 2-(2-cyclohexyl-ethylhydrazono)-propionic acid on redox systems, acid base status and monoamino oxidase activity. Horm Metab Res 12:182–189PubMedGoogle Scholar
  121. Oellerich M, Haeckel R, Wirries KH, Schumann G, Beneking M (1984) Hydrazonopropionic acids a new class of hypoglycemic substances. 4. Hypoglycemic effect of 2-(3-methyl-cinnamylhydrazono)-propionate in the rat and guinea pig. Horm Metab Res 16:619–625PubMedGoogle Scholar
  122. Panten U (1987) Rapid control of insulin secretion from pancretic islets. ISI Atlas of Science: Pharmacology 1:307–310Google Scholar
  123. Panten U, Burgfeld J, Goerke F, Rennicke M, Schwanstecher M, Wallasch A, Zünkler BJ, Lenzen S (1989) Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets. Biochem Pharmacol 38:1217–1229PubMedGoogle Scholar
  124. Passariello N, Sepe J, Marrazzo G, de Cicco A et al. (1993) Effect of aldose reductase inhibitor (tolrestat) on ordinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy. Diabetes Care 16:789–795PubMedGoogle Scholar
  125. Pedersen MM, Christiansen JS, Mogensen CE (1991) Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by 6 mo of aldose reductase inhibition. Diabetes 40:527–531PubMedGoogle Scholar
  126. Pirart J (1978) Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed between 1947 and 1973. Diabetes Care 1:168–188Google Scholar
  127. Plant TD, Henquin JC (1990) Phentolamine and yohimbine inhibit ATP-sensititve K channels in mouse pancreatic B-cells. Br J Pharmacol 101:115–120PubMedGoogle Scholar
  128. Porte D Jr (1967) A receptor mechanism for the inhibition of insulin release by epinephrine in man. J Clin Invest 46:86–94PubMedGoogle Scholar
  129. Profozic V, Babic D, Renar I, Rupprecht E, Skrabalo Z, Metelko Z (1993) Benzoic acid derivative hypoglycemic activity in non-insulin dependent diabetic patients. Diabetologia 36:Al83Google Scholar
  130. Pugazhenthi S, Khandelwal RL (1990) Insulin-like effects of vanadate on hepatic glycogen metabolism in non-diabetic and streptozotocin-induced diabetic rats. Diabetes 39:821–827PubMedGoogle Scholar
  131. Puls W, Bischoff H (1985) Hypoglycaemic effects of a novel dihydropyridine (DHP) analogue, Bay K 8644, in rats. Diabetes Res Clin Pract [Suppl 1]:457Google Scholar
  132. Randle PJ, Hales CN, Garland PB, Newsholme EA (1963) The glucose-fatty acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet i:785–789Google Scholar
  133. Ranganathan S, Krempf M, Feraille E, Charbonnel B (1993) Short-term effect of an aldose reductase inhibitor on urinary albumin excretion rate (UAER) and glomerular filtration rate (GRF) in type 1 diabetic patients with incipient nephropathy. Diabete Metab 19:257–261PubMedGoogle Scholar
  134. Ratheiser K, Schneeweiß B, Waldhäusl W, Fashcing P, Korn A, Nowotny P, Rohac M, Wolf HPO (1991) Inhibition by etomoxir of carnitine palmitoyltransferase 1 reduces hepatic glucose production and plasma lipids in non-insulin-dependent diabetes mellitus. Metabolism 40:1185–1190PubMedGoogle Scholar
  135. Ratheiser K, Korn A, Waldhaeusl W, Komjati M, Vierhapper H, Badian M, Malerczyk V (1993) Dose relationship of stimulated insulin production following intravenous application of glimepiride in healthy man. Arzneim-Forsch 43:856–858Google Scholar
  136. Reaven GM (1988) Role of insulin resistance in human disease. Diabetes 37:1595–1607PubMedGoogle Scholar
  137. Ribes G, Trimble ER, Blayac JP, Wollheim CB, Puech R, Loubatières-Mariani MM (1981) Effect of a new hypoglycaemic agent (HB 699) on the in vivo secretion of pancreatic hormones in the dog. Diabetologia 20:501–505PubMedGoogle Scholar
  138. Robertson RP (1986) Arachidonic acid metabolite regulation of insulin secretion. Diabetes Metab Rev 2:261–296PubMedGoogle Scholar
  139. Robertson RP, Porte D (1973) Adrenergic modulation of basal insulin secretion in man. Diabetes 22:1–8PubMedGoogle Scholar
  140. Robertson RP, Halter JB, Porte D (1976) A role for alpha-adrenergic receptors in abnormal insulin secretion in diabetes mellitus. J Clin Invest 57:791–795PubMedGoogle Scholar
  141. Ronner P, Higgins TJ, Kimmich GA (1991) Inhibition of ATP-sensitive K+-channels in pancreatic B-cells by nonsulfonylurea drug linogliride. Diabetes 40:885–892PubMedGoogle Scholar
  142. Ronner P, Hang TL, Kraebber MJ, Higgins TJ (1992) Effect of the hypoglycaemic drug (—)-AZ-DF-265 on ATP-sensitive potassium channels in rat pancreatic B-cells. Br J Pharmacol 106:250–255PubMedGoogle Scholar
  143. Rorsman P, Trube G (1986) Calcium and delayed potassium currents in mouse pancreatic B-cells under voltage-clamp conditions. J Physiol (Lond) 374:531–550Google Scholar
  144. Rossetti L, Laughlin MR (1989) Correction of chronic hyperglycemia with vanadate, but not with phlorizin normalizes in vivo glycogen repletion and in vitro glycogen synthase activity in diabetic skeletal muscle. J Clin Invest 84:892–899PubMedGoogle Scholar
  145. Sandouk T, Reda D, Hofmann C (1993) The antidiabetic agent pioglitazone increased expression of glucose transporters in 3T3-F442A cells by increasing messenger ribonucleic acid transcript stability. Endocrinology 133:352–359PubMedGoogle Scholar
  146. Santiago JV, Sonksen PH, Boulton AJ, Macleod A et al. (1993) Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group. J Diabetes Complications 71: 170–178Google Scholar
  147. Sato Y, Nishikawa M, Shinkai H, Sukegawa E (1991) Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-iso-propylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals. Diabetes Res Clin Pract 12:53–60PubMedGoogle Scholar
  148. Scherrer R, Mürtz H, Schmeidl R, Draeger E, Usadel KH (1988) Glimepiride-a very potent new sulfonylurea for treatment of type II diabetes. Diabetes 37: 136 AGoogle Scholar
  149. Schmidt FH, Deaciuc IV, Kühnle HF (1985) A new inhibitor of the long-chain fatty acid transfer across the mitochondrial membrane: 2-(3-methylcinnamylhy-drazono)-propionate (BM 42.304). Life Sci 36:63–67PubMedGoogle Scholar
  150. Schramm M, Thomas G, Towart R, Franckowiak G (1983) Novel dihydropyridines with positive inotropic action through activation of Ca2+ channels. Nature 303:535–537PubMedGoogle Scholar
  151. Schulz A, Hasselblatt A (1988) Phentolamine, a deceptive tool to investigate sympathetic nervous control of insulin release. Naunyn Schmiedebergs Arch Pharmacol 337:637–643PubMedGoogle Scholar
  152. Schulz A, Hasselblatt A (1989) An insulin-releasing property of imidazoline derivatives is not limited to compounds that block α-adrenoceptors. Naunyn Schmiedbergs Arch Pharmacol 340:321–327Google Scholar
  153. Selby PL, Sherratt HSA (1989) Substituted 2-oxiranecarboxylic acids: a new group of candidate hypoglycaemic drugs. TIPS 10:495–500PubMedGoogle Scholar
  154. Sener A, Malaisse WJ (1984) Nutrient metabolism in islet cells. Experientia 40: 1026–1035PubMedGoogle Scholar
  155. Shechter Y (1990) Insulin-mimetic effects of vanadate. Possible implications for future treatment of diabetes. Diabetes 39:1–5PubMedGoogle Scholar
  156. Shinkai H, Sato Y (1990) Hypoglycaemic action of phenylalanine derivatives. In: Bailey CJ, Flatt PR (eds) New antidiabetic drugs. Smith Gordon, London, pp 249–254Google Scholar
  157. Sima AA, Greene DA, Brown MB, Hohman TC et al. (1993) Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. J Diabetes Complications 7:157–169PubMedGoogle Scholar
  158. Sorbinil Retinopathy Trial Research Group (1990) A randomized trial of sorbinil, an aldose reductase inhibitor in diabetic retinopathy. Arch Opthalmol 108: 1234–1244Google Scholar
  159. Sorbinil Retinopathy Trial Research Group (1993) The sorbinil retinopathy trial: neuropathy results. Neurology 43:1141–1149Google Scholar
  160. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B et al. (1991) Retardation by aminoguanidine of development of albuminuria, mesangial expansion and tissue fluorescence in streptozotocin-induced diabetic rat. Diabetes 40:1328–4324PubMedGoogle Scholar
  161. Stern MP (1994) The insulin resistance syndrome. The controversy is dead, long live the controversy. Diabetologia 37:956–958PubMedGoogle Scholar
  162. Stevenson RW, Hutson NJ, Krupp MN, Volmann RA, Holland GF et al. (1990) Actions of novel antidiabetic agent englitazone in hyperglycemic ob/ob mice. Diabetes 39:1218–1227PubMedGoogle Scholar
  163. Stevenson RW, McPherson RK, Genereux PE, Danbury BH, Kreutter DK (1991) Antidiabetic agent englitazone enhances insulin action in nondiabetic rats without producing hyperglycemia. Metabolism 40:1268–1274PubMedGoogle Scholar
  164. Sugiyama Y, Taketomi S, Shimura Y, Ikeda H, Fujita T (1990a) Effects of pio-glitazone on glucose and lipid metabolism in Wistar fatty rats. Arzneim-Forsch 40:263–267Google Scholar
  165. Sugiyama Y, Shimura Y, Ikeda H (1990b) Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats. Arzneim-Forsch 40:436–440Google Scholar
  166. Sundkuist G, Armstrong FM, Bradbury JE, Chaplin C et al. (1992) Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat or placebo for 18 months. J Diabetes Complications 6:123–130Google Scholar
  167. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM (1992) Metabolic effects of new oral hypoglycemic agent CS 04S in NIDDM subjects. Diabetes Care 15:193–203PubMedGoogle Scholar
  168. Tadayyon M, Green I, Cook D, Pratt J (1987) Effect of a hypoglycemic agent M & B 29890 A on glucagon secretion in isolated rat islets of Langerhans. Diabetologia 30:41–43PubMedGoogle Scholar
  169. Taketomi S, Fujita T, Yokono K (1988) Insulin receptor and postbinding defects in KK mouse adipocytes and improvement by Ciglitazone. Diabetes Res Clin Pract 5:125–134PubMedGoogle Scholar
  170. Tamagawa T, Niki H, Niki A (1985) Insulin release independent of a rise in cytosolic free Ca2+ by forskolin and phorbol ester. FEBS Lett 183:430–432PubMedGoogle Scholar
  171. Tilton RG, Chang K, Hasan KS et al. (1993) Prevention of diabetic vascular dysfunction by guanidines. Diabetes 42:221–232PubMedGoogle Scholar
  172. Tomlinson DR, Stevens EJ, Diemel LT (1994) Aldose reductase inhibitors and their potential for treatment of diabetic complications. TIPS 15:293–297PubMedGoogle Scholar
  173. Tromp A, Hooymans JM, Barendsen BC, van Doormaal JJ (1991) The effect of an aldose reductase inhibitor on the progression of diabetic retinopathy. Documenta Opthalmologica 78:153–159Google Scholar
  174. Tsai SC, Burnakis TG (1993) Aldose reductase inhibitors: an update. Ann Pharmacother 27:751–754PubMedGoogle Scholar
  175. Tuman RW, Tutwiler GF, Bowden CR (1990) Linogliride: a guanidine insulin secretagogue. In: Bailey CJ, Flatt PR (eds) New antidiabetic drugs. Smith Gordon, London, pp 163–169Google Scholar
  176. Turk J, Wolf BA, McDaniel ML (1987) The role of phospholipid-derived mediators including arachidonic acid, its metabolites, and inositoltrisphosphate and of intracellular Ca2+ in glucose-induced insulin secretion by pancreatic islets. Prog Lipid Res 26:125–181PubMedGoogle Scholar
  177. Tutwiler GF, Dellevigne P (1979) Action of the oral hypoglycemic agent 2-tetra-decylglycidic acid on hepatic fatty acid oxidation and gluconeogenesis. J Biol Chem 254:2935–2941PubMedGoogle Scholar
  178. Tutwiler GF, Kirsch T, Mohnbacher R, Ho W (1978) Pharmacologic profile of methyl2-tetradecylglycidate (McN3716)-an orally effective hypoglycemic agent. Metabolism 27:1539–1555PubMedGoogle Scholar
  179. Tutwiler GF, Mohrbacher R, Ho W (1979) Methyl 2-tetradecylglycidate, an orally effective hypoglycemic agent that inhibits long chain fatty acid oxidation selectively. Diabetes 28:242–248PubMedGoogle Scholar
  180. Tutwiler GF, Tuman RW, Joseph JM, Mihan BB, Fawthrop H, Brentzel HJ (1986) Pharmacologic profile and insulin secretagogue effect of linogliride (McN-3935), a new orally effective hypoglycemic agent. Drug Dev Res 9:273–292Google Scholar
  181. Unson CG, Gurzenda EM, Merrifield RB (1989) Biological activities of des His [Glu9] glucagon amide, a glucagon antagonist. Peptides 10:1171–77PubMedGoogle Scholar
  182. Utter MF, Barden RE, Taylor BL (1975) Pyruvate carboxylase: an evaluation of the relationships between structure and mechanism and between structure and catalytic activity. Adv Enzymol Relat Areas Mol Biol 42:1–72PubMedGoogle Scholar
  183. Vaartjes WJ, De Haas CGM, Haagsman HP (1986) Effects of sodium 2–5-(4- chlorophenyl)pentyl-oxirane-2-carboxylate (POCA) on intermediary metabolism in isolated rat-liver cells. Biochem Pharmacol 35:4267–4272PubMedGoogle Scholar
  184. Van Praag HM, Leijnse B (1963) The influence of some antidepressant drugs of the hydrazine type on the glucose metabolism in depressed patients. Clin Chim Acta 8:466–475PubMedGoogle Scholar
  185. Verhaegen J, Leempoels J, Brugmans J, Tutwiler GF (1984) Preliminary evaluation of methyl palmoxirate (Me-Palm) in type I diabetes. Diabetes 33 [Suppl 1]:180AGoogle Scholar
  186. Vlassara H (1994) Recent progress on the biological and clinical significance of advanced glycosylation end products. J Lab Clin Med 124:19–30PubMedGoogle Scholar
  187. Wickstrom I, Petterson K (1964) Treatment of diabetics with monoamine oxidase inhibitors. Lancet 2:995–997PubMedGoogle Scholar
  188. Wolf HPO, Engel D (1985) Decrease of fatty acid oxidation, ketogenesis and gluconeogenesis in isolated perfused rat liver by phenylalkyl oxirane carboxylate (B 807–27) due to inhibition of CPT1 (EC Eur J Biochem 146: 359–363PubMedGoogle Scholar
  189. Wolff HP, Kühnle HF (1985) Synthesis and hypoglycemic activity of N-alkylated hydrazonopropionic acids. J Med Chem 28:1436–1440PubMedGoogle Scholar
  190. Wolf HPO, Eistetter K, Ludwig G (1982) Phenylalkyloxirane carboxylic acids, a new class of hypoglycemic substances: hypoglycemic and hypoketonaemic effects of sodium 2-[5-(4-chlorophenyl)pentyl]-oxirane-2-carboxylate (B 807–27) in fasted animals. Diabetologia 22:456–463PubMedGoogle Scholar
  191. Wolffenbüttel BHR, Nijst L, Sels JP, Menheere P, Müller PG, Nieuwenhuijzen-Kruseman AC (1992) Metabolic effect of a new oral hypoglycaemic agent, AGEE 623 ZW, in sulphonylurea (SU) treated type 2 diabetic patients. Diabetologia 35:A200Google Scholar
  192. Yada T, Fujitani S (1992) Action mechanisms of a novel hypoglycemic agent (A-4166) in pancreatic B-cells analyzed by measuring cytosolic Ca concentration. Diabetes 41:149AGoogle Scholar
  193. Yagihashi S, Kamijo M, Baba M, Yagihashi N, Nagai K (1992) Effect of amino-guanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes 41:47–52PubMedGoogle Scholar
  194. Yamanaka K, Kigoshi S, Muramatsu I (1984) The selectivity of DG-5128 as an α 2-adrenoceptor antagonist. Eur J Pharmacol 106:625–628PubMedGoogle Scholar
  195. Yamazaki H, Tabata S (1993) Sex difference in pharmacokinetics of the novel sulfonylurea antidiabetic glimepiride in rats. Arzneim-Forsch/Drug Res 43:1317–1321Google Scholar
  196. Yang C-W, Vlassara H, Peten EP, He C-J, Striker GE et al. (1994) Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 91:9436–9440PubMedGoogle Scholar
  197. Yen TT, Schmiegel KK, Gold G, Williams GD, Dininger NB, Broderick CL, Gill AM (1991) Compound M & B 39890 A [N-(3-imidazol-1-ylpropyl)-2-(3-trifluoromethylbenzenesulfonamido)-benzamide hydrochloride], a glucagon and insulin secretion inhibitor, improves insulin sensitivity in viable yellow obese-diabetic mice. Arch Int Pharmacodyn Ther 310:162–174PubMedGoogle Scholar
  198. Yoshioka S, Nishino H, Shiraki T, Ikeda K, Koike H et al. (1993) Antihypertensive effects of CS 045 treatment in obese Zucker rats. Metabolism 42:75–80PubMedGoogle Scholar
  199. Young DA, Ho RS, Bell PARH, Cohen DK, Mcintosh RH, Navelson J, Foley JE (1990) Inhibition of hepatic glucose production by SDZ 51641. Diabetes 39:1408–1413PubMedGoogle Scholar
  200. Yue DK, Brooks B (1993) The role of aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy. Med J Aust 159:76–78PubMedGoogle Scholar
  201. Zawalich WS, Rasmussen G, Tuman RW, Tutwiler GF (1987) Influence of the oral hypoglycemic agent linogliride (McN-3935) on insulin secretion from isolated rat islets of Langerhans. Endocrinology 120:880–885PubMedGoogle Scholar
  202. Zenon GJ, Abobo CY, Carter BL, Ball DW (1990) Potential use of aldose reductase inhibitors to prevent diabetic complications. Clin Pharmacy 9:446–456Google Scholar
  203. Ziegler D, Mayer P, Rathmann W, Gries FA (1991) One-year treatment with the aldose reductase inhibitor ponalrestat in diabetic neuropathy. Diabetes Res Clin Prac 14:63–74Google Scholar
  204. Zünkler BJ, Lenzen S, Männer K, Panten U, Trube G (1988) Concentration-dependent effects of tolbutamide, meglitinide, glipizide, glibenclamide and diazoxide on ATP-regulated K+ currents in pancreatic B-cells. Naunyn Schmiedebergs Arch Pharmacol 337:225–230PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • H. Bischoff
  • H. E. Lebovitz

There are no affiliations available

Personalised recommendations